login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

Avinger’s Ocelot catheter is CE marked


Thursday, 29 Sep 2011 11:21

Avinger has received CE mark approval for Ocelot ― a peripheral catheter system used with real-time Optical Coherence Tomography (OCT) for the treatment of peripheral artery disease.


According to Avinger, medical professionals, for the first time ever, will have access to a therapeutic device that incorporates real time intravascular guidance by using Ocelot’s Lightbox console as an adjunct to fluoroscopy.


“Ocelot CE mark is a long anticipated milestone for Avinger and a much larger milestone for me professionally. I have been working on uniting intravascular guidance with therapeutic products for 30 years and I am humbled that we have been able to achieve this at Avinger,” said John B Simpson, Avinger’s founder and CEO.


Avinger is currently enrolling patients in the VISTA study ― a single-centre, non-randomised registry designed to evaluate the safety and efficacy of Ocelot in patients with peripheral artery disease. The registry is being developed in Paraguay, with Adrian Ebner of Sanitorio Italiano in Asunción, as the principal investigator.


European comercialisation of Ocelot has already begun. The first three commercial cases are scheduled to be performed in Italy and Germany in late September and early October.

 




Add New Comment

Most popular


One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms
Wednesday, 29 Apr 2015
Results from the 12-month data of the randomised controlled IMPROVE trial show that an endovascular strategy is cost-effective when compared to open repair in the treatment of ruptured abdominal ... One-year IMPROVE data suggest benefit of EVAR in ruptured aneurysms

 Yasuaki Arai gets standing ovation after ECIO Honorary Lecture
Friday, 24 Apr 2015
Yasuaki Arai, director of the National Cancer Center Hospital, Tokyo, Japan, and current president of the Japanese Society of Interventional Radiology (JSIR), delivered the Honorary Lecture at the E...  Yasuaki Arai gets standing ovation after ECIO Honorary Lecture

First patient enrolled in Vessix sham-controlled study
Friday, 17 Apr 2015
Boston Scientific has announced that it is taking a new approach to evaluate the performance of its Vessix renal Denervation System. It says it is initiating a study with a novel design to isolate ... First patient enrolled in Vessix sham-controlled study

Features


The challenges of measuring response in interventional oncology
Monday, 30 Mar 2015
An overview of three treatments: ablation, chemoembolization and selective interval radiation therapy, should clarify the challenges of determining tumour response in interventional oncology, write M... The challenges of measuring response in interventional oncology

Revolutionary focused ultrasound still needs to address limitations
Monday, 30 Mar 2015
Alessandro Napoli writes that therapeutic ultrasound still has some technological hurdles that need to be overcome, despite his success with the treatment over the past five years. Revolutionary focused ultrasound still needs to address limitations

Profiles


Lindsay Machan
Thursday, 28 May 2015
“Focussing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions